TrialScope’s Board of Directors oversees our leaders and works with the team to set the direction for TrialScope to excel as a clinical transparency leader.

Marc Lederman

Marc Lederman

Co-Founder, NewSpring Capital

Marc Lederman is a co-founder of NewSpring and a General Partner of the Firm’s dedicated growth equity funds. He serves as a member of the investment committee of all NewSpring Growth and NewSpring Mezzanine funds.

Marc has an extensive background in finance, investing, consulting, and accounting and was a Certified Public Accountant. Prior to co-founding NewSpring, he was a Manager in the Business Assurance and Advisory Services Group of Deloitte. Marc is an active member of the Mid-Atlantic region’s private equity and venture capital community.

He received a BS in Accountancy from Villanova University and an MBA from The Wharton School of the University of Pennsylvania.

Larry Berran

Larry Berran

CFO/COO, iPipeline

Larry joined iPipeline in 2002, and served as President and CEO of the company through July 2008. Larry transitioned to the Chief Operating Officer and Chief Financial Officer positions in July 2008 in connection with a combined recapitalization of iPipeline and an acquisition of a key partner. During his tenure, Larry has been a key driver of growing iPipeline from $1 million in revenue to over $150 million and completing 10 strategic acquisitions in the US, UK and Canada.

Larry has raised over $0.5 billion in equity and debt proceeds for the Company and it investors for acquisitions, working capital and highly successful exits for NewSpring Capital, Alimont (fka Fidelity Ventures), Technology Crossover Ventures, Square 1 Bank, Capital One Bank and Wells Fargo.

Prior to iPipeline, Larry was a Vice President for ICG, where he played an instrumental role in preparing ICG for its 1999 initial public offering. During this time, Larry was directly involved with organizing and implementing ICG’s finance function, including raising over $1.6 billion through multiple issuances of publicly traded securities, as well as bank and private financings.

Larry has also held management positions with Safeguard Scientifics and worked as a CPA with PWC specializing in insurance and financial services. Larry’s prior board and public service have included The Sycamore Group, Philadelphia Children’s Alliance, ARI Mutual Insurance Company, and coaching girls soccer and basketball. Larry currently serves as a board director for Trial Scope (including Compensation Cte and Chair of Audit Cte).

Larry graduated in 1993 from La Salle University in Philadelphia, Pennsylvania with a Bachelor of Science degree. He has two daughters and resides in West Chester, PA.

Jeff Kozloff

Jeff Kozloff

CEO, TrialScope. Co-founder and former CEO of Verilogue.

Jeff is a serial healthcare entrepreneur with over 18 years of pharmaceutical experience. Before taking over as TrialScope CEO in 2018, Jeff served on the Company’s Board of Directors for more than two years.

Jeff is a serial healthcare entrepreneur with over 18 years of pharmaceutical experience. Before taking over as TrialScope CEO in 2018, Jeff served on the Company’s Board of Directors for more than two years.

Prior to TrialScope, Jeff was the founder of two successful healthcare technology companies, HeroLinx and Verilogue. HeroLinx is an online crowdsourcing platform for accelerating clinical trial awareness and patient recruiting.  Verilogue, which was acquired by Publicis (PUB:FP), is the global leader in the capture and linguistic analysis of physician-patient exam room dialogues.

Jeff also previously served on the Board of Directors for iContracts, a SaaS compliance and revenue management company, and he remains an active angel investor and advisor to a half-dozen software and analytics companies.

Jeff holds a BS in Economics from the Wharton School at the University of Pennsylvania, and is the co-author of a method and system patent for analyzing the effectiveness of marketing strategies.

Michael Kopelman

Michael Kopelman

General Partner, Edison Partners

Michael has nearly 20 years of venture investing, corporate finance and entrepreneurship with software, e-commerce and financial services organizations. Michael leads Edison's Fintech practice. He also guides the investment team in Pennsylvania and Delaware. Michael is a frequent speaker at entrepreneurial events, technology conferences and financing seminars.

Michael began his career as an investment banker with Credit Suisse First Boston where he advised large retail and consumer products companies on numerous M&A and financing transactions. In 1999, Michael left CSFB to launch E*OFFERING, a venture-backed online investment bank affiliated with E*TRADE. He launched several new online products, including the first web-based roadshow for retail investors. E*OFFERING was acquired one year after its launch by SoundView Technology Group, where he remained to lead the firm’s internet & e-commerce investment banking franchise.

Michael is active in regional venture, entrepreneurial and technology organizations, including PACT, ACG and Early Stage East. He is currently Co-President of Wharton Private Equity Partners and past Co-Chair of the Wharton Private Equity Conference.

His education includes a BA in Economcs from the University of Pennsylvania, and an MBA from The Wharton School.

Jim Walker

Jim Walker

Founder, Octagon Research Solutions, Inc.

James C. Walker has been working in the pharmaceutical industry for 20 years. He is the founder of Octagon Research Solutions, Inc. Prior to founding Octagon, he worked as the Senior Manager of Worldwide Regulatory Affairs for the Schering-Plough Corporation (“Schering”).

While at Schering, he was responsible for clinical and pre-clinical in the antihistamine, central nervous system, and critical care therapeutic areas.

Prior to joining Schering, Mr. Walker worked across multiple therapeutic areas in the Regulatory Affairs/Clinical and Clinical Quality Assurance department at the R.W. Johnson Pharmaceutical Research Institute (PRI). Mr. Walker has extensive experience in and knowledge of all phases of clinical research and both FDA and European regulations. He is skilled at process improvement and providing insight across multiple disciplines within drug development. Mr. Walker holds a B.S. in Biological Sciences from Villanova University, a Masters in Environmental Sciences from Rutgers University, and an M.B.A. from Duke University.